leiomyosarcoma


Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to leiomyosarcoma

sarcoma of smooth muscle

Related Words

References in periodicals archive ?
A new Food and Drug Administration literature review of 23 studies found consistent evidence that women could develop leiomyosarcomas and other uterine cancers after undergoing surgery using laparoscopic power morcellators (LPMs) for fibroids that were assumed to be benign.
However, after a literature search of previous studies, the Food and Drug Administration (FDA) announced that the prevalence of unsuspected uterine sarcoma in patients undergoing hysterectomy or myomectomy for a presumed benign leiomyoma was 1 in 352 and the prevalence of an unsuspected uterine leiomyosarcoma was 1 in 498.
Primary Leiomyosarcoma of the Mesentery: A Case Report.
Among these, the most important one is leiomyosarcoma, which shows similar properties with leiomyomas in that it appears as a dense, well-demarcated non-invasive lesion on mammography and arises many years before being diagnosed.
Key words: leiomyosarcoma, smooth muscle neoplasm, immunohistochemistry, avian, Vieilott's fireback pheasant, Lophura rufa
Challenges commonly arise when some but not all histologic features of a leiomyosarcoma are present.
According to the results of preplanned subgroup analyses of the duration of response in patients with liposarcoma and leiomyosarcoma, median duration of response for the eribulin treatment was 12.
The family breadwinner was spending the holidays with her mother and sister when she was found to have leiomyosarcoma.
Pathologist Dr Jennifer Bolton said that Mrs Scully's entire uterus was a tumour at the time of her death from the rare and aggressive leiomyosarcoma type of cancer.
The differential diagnosis includes renal cell carcinoma, angiomyolipoma, leiomyosarcoma, and oncocytoma.
Leiomyosarcoma is an aggressive tumor with a high local recurrence rate as well as significant hematogenous spread.
It also reviews key players involved in the therapeutic development for Leiomyosarcoma and special features on late-stage and discontinued projects.